{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PEG-IFN+alfa-2a&page=3", "query": { "intervention": "PEG-IFN alfa-2a", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 199, "total_pages": 20, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PEG-IFN+alfa-2a&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PEG-IFN+alfa-2a&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-01T16:24:03.420Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01318694", "title": "Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Alisporivir", "type": "DRUG" }, { "name": "Peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "ALV Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Debiopharm International SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 1081, "start_date": "2011-03", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2016-09-30", "last_synced_at": "2026-10-01T16:24:03.420Z", "location_count": 32, "location_summary": "Beverly Hills, California • Oakland, California • San Diego, California + 23 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01318694" }, { "nct_id": "NCT00869661", "title": "A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Copegus", "type": "DRUG" }, { "name": "Pegasys", "type": "DRUG" }, { "name": "RO5024048", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 413, "start_date": "2001-02", "completion_date": "2012-02", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-10-01T16:24:03.420Z", "location_count": 21, "location_summary": "Birmingham, Alabama • La Jolla, California • Sacramento, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00869661" }, { "nct_id": "NCT01389323", "title": "BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Daclatasvir", "type": "DRUG" }, { "name": "Peg-Interferon Alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 448, "start_date": "2011-09", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2015-10-12", "last_synced_at": "2026-10-01T16:24:03.420Z", "location_count": 35, "location_summary": "Montgomery, Alabama • Long Beach, California • Los Angeles, California + 24 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01389323" }, { "nct_id": "NCT01758588", "title": "Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelofibrosis" ], "interventions": [ { "name": "Peginterferon alfa-2a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2013-01", "completion_date": "2017-06", "has_results": true, "last_update_posted_date": "2018-07-24", "last_synced_at": "2026-10-01T16:24:03.420Z", "location_count": 2, "location_summary": "Atlanta, Georgia • New York, New York", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01758588" }, { "nct_id": "NCT00394277", "title": "A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1175, "start_date": "2007-02", "completion_date": "2009-04", "has_results": true, "last_update_posted_date": "2010-08-03", "last_synced_at": "2026-10-01T16:24:03.420Z", "location_count": 91, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 74 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00394277" }, { "nct_id": "NCT00874770", "title": "Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Infection" ], "interventions": [ { "name": "Daclatasvir", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Peginterferon alpha-2a", "type": "DRUG" }, { "name": "ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 74, "start_date": "2009-06", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2015-10-23", "last_synced_at": "2026-10-01T16:24:03.420Z", "location_count": 11, "location_summary": "Montgomery, Alabama • Aurora, Colorado • New Haven, Connecticut + 7 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Springfield", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00874770" }, { "nct_id": "NCT00594880", "title": "Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Pegylated Interferon-alpha 2a, 180 mcg/week sc", "type": "DRUG" }, { "name": "Pegylated Interferon-alpha 2a, 90 mcg/week sc", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Wistar Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 23, "start_date": "2008-01", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2015-02-10", "last_synced_at": "2026-10-01T16:24:03.420Z", "location_count": 5, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00594880" }, { "nct_id": "NCT00100659", "title": "PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "Pegylated Interferon/ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "5 Years to 18 Years" }, "enrollment_count": 114, "start_date": "2004-12", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2018-10-24", "last_synced_at": "2026-10-01T16:24:03.420Z", "location_count": 11, "location_summary": "San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 8 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00100659" }, { "nct_id": "NCT03575208", "title": "Hepatitis B Immune Globulin (HBIg) to Restore Immune Control in People With Chronic Hepatitis B", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis B" ], "interventions": [ { "name": "hepatitis B immune globulin (HBIg)", "type": "BIOLOGICAL" }, { "name": "Pegylated interferon alfa (pegIFN)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-02-13", "completion_date": "2022-03-29", "has_results": false, "last_update_posted_date": "2022-04-06", "last_synced_at": "2026-10-01T16:24:03.420Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03575208" }, { "nct_id": "NCT00395421", "title": "Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "NM283 plus Peg-IFNα-2a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 114, "start_date": "2006-10", "completion_date": "2008-08", "has_results": false, "last_update_posted_date": "2010-06-10", "last_synced_at": "2026-10-01T16:24:03.420Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Fairfax, Virginia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00395421" } ] }